Phaseline

Targets › TGFBR2

TGFBR2 (TGF-beta receptor type-2): drug programs, companies and trials

7 programs from 3 companies in 11 trials: 10 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.

Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells,…. (UniProt, P37173)

Open in Phaseline: the race on TGFBR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2868 injection
Anti-PD-1/TGF-βRII bifunctional fusion protein
PDCD1, TGFBR2Phase 2Pancreatic NeoplasmsNov 2026
M.D. Anderson Cancer CenterCB-NK-TGF-betaR2-/NR3C1-
Cord blood-derived engineered natural killer cells with deleted TGF-betaR2 and NR3C1 (gluc
TGFBR2, NR3C1Phase 1Recurrent GliosarcomaJan 2027
M.D. Anderson Cancer CenterCytokine-treated Veto Cells
CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel
IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2Phase 1Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal CancerDec 2027
M.D. Anderson Cancer CenterTROP2 CAR/IL-15 TGFBR2 KO NK cells
CAR-T cell therapy targeting TROP2 with IL-15 transduction and TGFBR2 knockout in cord blo
TROP2, IL15, TGFBR2Phase 1Head and Neck CancerDec 2027
M.D. Anderson Cancer CenterTGFBR2 KO CAR27/IL-15 NK cells
TGFBR2 knock-out cord blood-derived NK cells transduced with IL-15 and engineered with CAR
TGFBR2, IL15Phase 1Myeloid MalignanciesMay 2028
M.D. Anderson Cancer CenterTGFBR2 KO CAR27/IL-15 NK cells
TROP2-targeted CAR-NK cells with IL-15 co-expression and TGFBR2 knockout
TROP2, TGFBR2, IL15Phase 1Gastric Cancer, Metastatic; LymphoidJul 2028
University of ChicagoNY-ESO-1 TCR/ dnTGFβRII
Gene-modified T cells expressing NY-ESO-1-specific T cell receptor and dominant-negative T
TRA, TRB, TGFBR2Phase 1Ovarian CancerDec 2031

Conditions

Gastric Cancer, Metastatic (1) Lymphoid (1) Myeloid Malignancies (1) Ovarian Cancer (1) Pancreatic Neoplasms (1) Acute Lymphoblastic Leukemia (1) Acute Myeloid Leukemia (1) Phase 1 (1) Colorectal Cancer (1) Head and Neck Cancer (1) Recurrent Gliosarcoma (1)

Modalities

mixed (5), small molecule (1), other (1)

Companies

M.D. Anderson Cancer Center (5) University of Chicago (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1)

Related targets

TROP2 (3) IL15 (3) NR3C1 (2) TRA (1) TRB (1) PDCD1 (1) IL13RA1 (1) EGFR (1) IL21 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.